Company Description
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States.
The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data.
In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period.
It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products.
iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Oct 20, 2016 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 2,000 |
| CEO | Quentin Blackford |
Contact Details
Address: 699 8th Street, Suite 600 San Francisco, California 94103 United States | |
| Phone | 415 632 5700 |
| Website | irhythmtech.com |
Stock Details
| Ticker Symbol | IRTC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001388658 |
| CUSIP Number | 450056106 |
| ISIN Number | US4500561067 |
| Employer ID | 20-8149544 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Quentin S. Blackford | President, Chief Executive Officer and Director |
| Dr. Minang P. Turakhia M.D., M.S. | Chief Medical and Scientific Officer and Executive Vice President of Product Innovation |
| Patrick Michael Murphy J.D. | Chief Business and Legal Officer |
| Chad M. Patterson | Chief Commercial Officer |
| Daniel G. Wilson | Chief Financial Officer, Principal Financial Officer, Executive Vice President of Corporate Development and Investor Relations |
| Mervin Smith | Executive Vice President of Business Operations |
| Marc Rosenbaum | Senior Vice President of Finance and Chief Accounting Officer |
| Sumi Shrishrimal | Executive Vice President and Chief Risk Officer |
| Stephanie Zhadkevich | Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2025 | 144 | Filing |
| Feb 20, 2025 | 10-K | Annual Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Jan 27, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 8, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |